← Back to Clinical Trials
Recruiting NCT06918860

NCT06918860 Analysis of Intramedullary Nail and Prosthetic Reconstruction After Surgical Treatment of Bone Metastases of Proximal Femur

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06918860
Status Recruiting
Phase
Sponsor Costantino Errani
Condition Bone Metastases
Study Type OBSERVATIONAL
Enrollment 600 participants
Start Date 2024-05-30
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Analysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 600 participants in total. It began in 2024-05-30 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators will collect data of patients treated surgically for impending or pathological fracture of the proximal femur due to bone metastases between 01/01/2000 and 31/12/2023 with IMN or THA or HHA or MegaTHA or Mega. After pre-screening the databases of the respective sites, the investigators expect to find approximately a total of 600 patients. A review will be made from the medical records, radiological imaging, and histological data of partecipants.

Eligibility Criteria

Inclusion Criteria: * Male and female adult patients surgically treated between 01/01/2000 and 31/12/2023 in Rizzoli Orthopaedic Institute and in Massachusetts General Hospital. * Age ≥18 y (at the time of surgery) * Patients with impending or pathological fracture due to bone metastases of the proximal femur (head/neck, intertrochanteric, subtrochanteric area). * Patients who underwent either IMN or THA or HHA or Mega or MegaTHA. * Patients with available clinical and imaging data. Exclusion Criteria: * Patients with pathological or impending fracture of proximal femur due to primary bone tumor.

Contact & Investigator

Central Contact

Costantino Errani, MD

✉ costantino.errani@ior.it

📞 0516366

Frequently Asked Questions

Who can join the NCT06918860 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Bone Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06918860 currently recruiting?

Yes, NCT06918860 is actively recruiting participants. Contact the research team at costantino.errani@ior.it for enrollment information.

Where is the NCT06918860 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06918860 clinical trial?

NCT06918860 is sponsored by Costantino Errani. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology